Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Clinical Imbalances

Immune and inflammation

Modifiable Lifestyle Factors

Diet

Laboratory Testing

Blood

Imaging

Text Availability

Abstract

430

Full text

327

Free full text

256

Publication Types

Journal Article

419

Research Support, Non-U.S. Gov't

180

Multicenter Study

178

Randomized Controlled Trial

147

Clinical Trial, Phase II

118

Clinical Trial, Phase III

Comparative Study

Meta-Analysis

Observational Study

Systematic Review

Research Support, N.I.H., Extramural

Clinical Trial, Phase I

Review

Clinical Trial

Clinical Trial Protocol

Network Meta-Analysis

Equivalence Trial

Comment

Research Support, U.S. Gov't, Non-P.H.S.

Evaluation Study

News

Research Support, N.I.H., Intramural

Validation Study

Research Support, U.S. Gov't, P.H.S.

Controlled Clinical Trial

Editorial

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

110

2020

2019

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Progression-Free Survival""[mesh_terms]

435 Results

Searching titles within these results

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.

Kohei Shitara, Motohiro Hirao, Satoru Iwasa, Takashi Oshima, Yoshito Komatsu, Akihito Kawazoe, Yasuyoshi Sato, Takuya Hamakawa, Kan Yonemori, Nozomu Machida, Satoshi Yuki, Takuya Suzuki, Shiori Okumura, Takao Takase, Taro Semba, Bob Zimmermann, Angela Teng, Kensei Yamaguchi

Clinical cancer research : an official journal of the American Association for Cancer Research 2023;29(8):1460-1467

Filters

Expert Opinion

Clinical Imbalances

Modifiable Lifestyle Factors

Laboratory Testing

Text Availability

Publication Types

Publication Year

Results for ""Progression-Free Survival""[mesh_terms]

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.

A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.

Ferroptosis is a protective factor for the prognosis of cancer patients: a systematic review and meta-analysis.

Locoregional therapy containing surgery in metastatic breast cancer: Systematic review and meta-analysis.

Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials.

Role of nutritional adjuncts in the management of gliomas: A systematic review of literature.

Prognostic and clinicopathological significance of the Controlling Nutritional Status (CONUT) score in patients with lymphoma: a meta-analysis.

Prognostic value of pretreatment Controlling Nutritional Status score in esophageal cancer: a meta-analysis.

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.

CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.

The effects of statin therapy on brain tumors, particularly glioma: a review.

Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis.

Prognostic Nutritional Index (PNI) as Independent Predictor of Poor Survival in Prostate Cancer: A Systematic Review and Meta-Analysis.

Prognostic and clinicopathological effect of the prognostic nutritional index (PNI) in patients with cervical cancer: a meta-analysis.

A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?

Results for
""Progression-Free Survival""[mesh_terms]